Pharma CEO Succession: Commit to a single candidate five years out, or keep a candidate slate and converge gradually using strategy, board, and readiness gates?
Current product policyLast updated September 30, 2026
Recommendation: retain the candidate slate and converge gradually through strategy, readiness, and governance gates, as this preserves adjustability over the five-year uncertain horizon while balancing fairness and retention (F1, F2, F3, F6)
Decision owner in the teaching simulationChair of the Board CEO Succession Committee, in an independent instructional simulation
Human-controlled next action
Action: the succession committee leads development of a concrete governance-gate design proposal for the candidate slate (confidentiality, fairness, conflicts of interest, reversal thresholds) before the next board meeting
What would reverse the recommendation
Reversal condition: if evidence shows the incumbent CEO's or board's preferences (F5) have substantively driven candidate screening, rendering the slate mechanism nominal, switch to a more transparent single-path approach or restructure governance
Decision review illustration
AI-generated illustration, not an actual customer scene or product screenshot. It does not demonstrate outcomes or imply endorsement.
Evidence and endorsement boundary:Independent teaching simulation. The named consulting firm supplied the public source only; it did not use, review, endorse, sponsor, certify or commission Minerva Advisor. This evidence does not claim customer results, ROI or a permanent service-level guarantee.
Inspect the evidence, then test your own decision context.
Bring a real, de-identified decision. Google sign-in and product access are required; your plan and Decision Credits apply. You remain the decision-maker, and no email or external action is sent automatically.